58 completed, 11 unknown, 10 recruiting, 6 not yet recruiting. 45 Not applicable, 20 Phase 3, 9 Phase 4, 7 Phase 2, 3 Phase 1.
Follow Attention Deficit Hyperactivity Disorder (ADHD): new trials by email Literature Review of Attention Deficit Hyperactivity Disorder (ADHD) trials Research Report on Attention Deficit Hyperactivity Disorder (ADHD)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Micronutrient Supplementation and Chronotherapy in Children With ADHD Broad-spectrum multivitamin and mineral supplementation, Chronotherapy-Based Lifestyle Guidance - Attention Deficit Hyperactivity Disorder (ADHD) | Not applicable | Recruiting | UCSI University | 120 | 2027-01-01 | 2026-11-06 |
| Cognitive-Motor Training With the DextEgg in Children With ADHD Cognitive-motor DextEgg training, Motor-only DextEgg training - Attention Deficit Hyperactivity Disorder (ADHD) | Not applicable | Not yet recruiting | Manuela Pastore-Wapp | 50 | 2026-11-01 | 2026-11-05 |
| Methodology of Super-Early Training of Developer Engineers and Leading Analysts With a Diagnosis of ADHD/ASD for Ensuring the Engineering Sovereignty of the State: Time Horizon: 2026-2038-2050 Voice of Sleep "MamaBee" training modules (Fairy Tales) - Attention Deficit Hyperactivity Disorder (ADHD) | Not applicable | Active not recruiting | Pisareva Citadel Group LLC | 2 | 2026-08-01 | 2026-09-28 |
| Effects of Probiotics on the Gut-brain Axis in Children Probiotics, Placebo - Attention Deficit Hyperactivity Disorder (ADHD) | Not applicable | Recruiting | Probi AB | 80 | 2026-05-25 | 2026-07-07 |
| Virtual Reality Supported Rehabilitation for Children's Executive and Metaphonological Skills vrrs, Treatment as usual - Attention Deficit Hyperactivity Disorder (ADHD) | Not applicable | Not yet recruiting | IRCCS Centro Neurolesi Bonino Pulejo | 50 | 2026-03-31 | 2026-02-23 |
| Mindfulness ADHD Intervention Guided deep breathing - Attention Deficit Hyperactivity Disorder (ADHD) | Not applicable | Enrolling by invitation | Boston Children's Hospital | 10 | 2026-02-26 | 2026-03-31 |
| The TEAM Study - Treatment Efficacy for Autism/Attention Using Mixed Amphetamine Adderall XR (mixed salts amphetamine), Placebo - Attention Deficit Hyperactivity Disorder (ADHD), Autism | Phase 4 | Recruiting | Gagan Joshi | 196 | 2026-02-01 | 2026-03-06 |
| Transcranial Photobiomodulation With Multiple Interventions in Children With Attention-Deficit/Hyperactivity Disorder Transcranial photobiomodulation (active), Transcranial photobiomodulation (sham) - Attention Deficit Hyperactivity Disorder (ADHD) | Not applicable | Not yet recruiting | Qilu Hospital of Shandong University | 54 | 2025-10-01 | 2025-10-06 |
| Effectiveness of Manual Therapy in the Treatment of Attention Deficit Hyperactivity Disorder Procedure: craniosacral therapy techniques., Placebo Group - Attention Deficit Hyperactivity Disorder (ADHD) | Not applicable | Not yet recruiting | JJ JIMENEZ-REJANO | 60 | 2025-10-01 | 2025-06-27 |
| L-theanine and Paraxanthine for Cognitive Improvement in Adults With ADHD and ASD L-theanine and paraxanthine, Placebo - Attention Deficit Hyperactivity Disorder (ADHD), Autism Spectrum Disorder (ASD) | Not applicable | Completed | Texas Tech University Health Sciences Center | 17 | 2025-10-01 | 2026-08-24 |
| Improving ADHD Teen Driving - Virtual Reality FOCAL+, VR-FOCAL+ - Attention Deficit Hyperactivity Disorder (ADHD) | Not applicable | Recruiting | Children's Hospital Medical Center, Cincinnati | 204 | 2025-09-11 | 2026-02-23 |
| PHArmaCokinetics of methYLphenidate in Adult Patients With Attention-Deficit /Hyperactivity Disorder PHArmacoKinetics of methYLphenidate in adult patients with ADHD: comparison between patients with and without OBesity. - Attention Deficit Hyperactivity Disorder (ADHD), Obesity (Body Mass Index &Amp;Amp;gt;30 kg/m2) | Phase 4 | Not yet recruiting | University Hospital, Tours | 30 | 2025-09-01 | 2025-08-13 |
| A Random Controlled Trial of Home-based Digital Therapy for Treating ADHD in Children Home-based digital therapy with brain-controlled games - Attention Deficit Hyperactivity Disorder (ADHD) | Not applicable | Recruiting | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | 146 | 2025-08-24 | 2026-09-08 |
| A Long-term Trial of EB-1020 in Adult Patients With ADHD EB-1020 (Centanafadine) 164.4 mg, EB-1020 (Centanafadine) 328.8 mg - Attention Deficit Hyperactivity Disorder (ADHD) | Phase 3 | Recruiting | Otsuka Pharmaceutical Co., Ltd. | 180 | 2025-06-25 | 2026-10-23 |
| Examination of the Dynamic Relationships of Sleep, Physical Activity, and Circadian Rhythmicity With Neurobehavioral Heterogeneity in ADHD Go/No-Go Task, Delay discounting task, Mirror Tracing Persistence Task - Attention Deficit Hyperactivity Disorder (ADHD), Sleep | Not applicable | Recruiting | Hugo W. Moser Research Institute at Kennedy Krieger, Inc. | 200 | 2025-06-17 | 2026-03-09 |
| Prediction of ADHD in Children Using Pedobarographic and Postural Data Attention Deficit Hyperactivity Disorder (ADHD) | Recruiting | Biruni University | 100 | 2025-05-09 | 2025-09-18 | |
| Home-Based Executive Function Training Intervention For Attention-Deficit/ Hyperactivity Disorder-prone Children Home-based executive function training therapy - Attention Deficit Hyperactivity Disorder (ADHD) | Not applicable | Not yet recruiting | Wuhan Mental Health Centre | 100 | 2025-05-01 | 2025-04-30 |
| Evaluation of the Efficacy and Safety of EB-1020 in Adult ADHD Patients EB-1020 (Centanafadine) 164.4 mg, EB-1020 (Centanafadine) 328.8 mg, Placebo - Attention Deficit Hyperactivity Disorder (ADHD) | Phase 2 / Phase 3 | Recruiting | Otsuka Pharmaceutical Co., Ltd. | 630 | 2025-04-30 | 2026-10-23 |
| Deficit Hyperactivity Disorder / Substance Use Disorder Comorbidity in Integrated Treatment TAU+integrated group CBT - Attention Deficit Hyperactivity Disorder (ADHD), Substance-related Disorder | Not applicable | Recruiting | Assistance Publique - Hôpitaux de Paris | 132 | 2025-04-01 | 2025-06-26 |
| Mental Health, Intellectual and Neurodevelopmental Disorder Detection With Artificial Intelligence Models Solicue Machine Learning Models, Mercuria Machine Learning Models - Autism Spectrum Disorder, Depression - Major Depressive Disorder | Enrolling by invitation | Psyrin Inc. | 500 | 2025-02-04 | 2025-09-03 |
Showing 20 of 98. Sign in to see all of them.
Attention Deficit Disorder with Hyperactivity (98) · Autism Spectrum Disorder (8) · Spasm (8) · Anxiety Disorders (4) · Motor Activity (4) · Autistic Disorder (3) · Impulsive Behavior (2) · Marijuana Abuse (2) · Neurodevelopmental Disorders (2) · Psychological Well-Being (2) · Substance-Related Disorders (2) · Adjustment Disorders (1) · Behavior (1) · Binge-Eating Disorder (1) · Bipolar Disorder (1)
Attention Deficit and Disruptive Behavior Disorders (98) · Mental Disorders (98) · Neurodevelopmental Disorders (96) · Nervous System Diseases (11) · Pathological Conditions, Signs and Symptoms (11) · Behavior (10) · Neurologic Manifestations (10) · Signs and Symptoms (10) · Child Development Disorders, Pervasive (8) · Neuromuscular Manifestations (8) · Chemically-Induced Disorders (5) · Substance-Related Disorders (3) · Trauma and Stressor Related Disorders (3) · Behavioral Symptoms (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2)
Lisdexamfetamine Dimesylate (9) · Methylphenidate (9) · Atomoxetine Hydrochloride (5) · Dextroamphetamine (3) · Therapeutics (3) · 1-(naphthalen-2-yl)-3-azabicyclo(3.1.0)hexane (2) · Adderall (2) · Amphetamine (2) · Exercise (2) · Fatty Acids, Omega-3 (2) · Guanfacine (2) · Probiotics (2) · SLI381 (2) · 1,7-dimethylxanthine (1) · 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-amine (1)
Shire (15) · Massachusetts General Hospital (4) · Supernus Pharmaceuticals, Inc. (4) · Assistance Publique - Hôpitaux de Paris (3) · King's College London (3) · Children's Hospital Medical Center, Cincinnati (2) · McGill University Health Centre/Research Institute of the McGill University Health Centre (2) · Otsuka Pharmaceutical Co., Ltd. (2) · Pfizer (2) · Takeda (2) · University of California, Los Angeles (2) · University of Nottingham (2) · Wuhan Mental Health Centre (2) · Alcobra Ltd. (1) · Arbor Pharmaceuticals, Inc. (1)
United States (42) · United Kingdom (10) · China (6) · Spain (6) · France (5) · Germany (5) · Sweden (5) · Turkey (Türkiye) (5) · Canada (4) · Belgium (3) · Italy (3) · Netherlands (3) · Hungary (2) · Israel (2) · Japan (2)
James J. McGough, M.D. (2) · Lily Hechtman, MD, FRCPC (2) · Nobuhito Sanada (2) · Sandra K. Loo, Ph.D. (2) · Amy L Moore, PhD (1) · Ana Bielsa, MD (1) · Anna N. Platonova, Cand.Med.Sci, MD (1) · Anna S. Nezabudkina, MD (1) · Atta-ul Raheem R Chaudhry, B.Sc. (Hons.), M.B.B.S. (1) · Azmi Nasser, PhD (1) · Carolyn Sikes, PhD (1)
PMID 18503531, PMID 20035583, PMID 21173426, PMID 21186969, PMID 21421179, PMID 22146580, PMID 24787685, PMID 25807129, PMID 25928870, PMID 26207130, PMID 26608976, PMID 26748531, PMID 26771913, PMID 26912485, PMID 27118284, PMID 27178060, PMID 27183299, PMID 27238063, PMID 27426904, PMID 27631143, PMID 27866283, PMID 28183284, PMID 28576350, PMID 28667569, PMID 28712074, PMID 28816509, PMID 29098467, PMID 29383572, PMID 29442229, PMID 29700813, PMID 29790103, PMID 30096196, PMID 30768393, PMID 30972657, PMID 32233956, PMID 32304847, PMID 33068751, PMID 33114154, PMID 33159336, PMID 33185468, PMID 33740903, PMID 34081560, PMID 34826114, PMID 35201607, PMID 35230142, PMID 35441908, PMID 35577034, PMID 35928417, PMID 36443712, PMID 36845650
R34MH101282 (3), 2023 (1), R01HD070821 (1), R01HD084430 (1), R43MH099709 (1)